Novo Nordisk · 21 hours ago
Internship - Rare Disease Community Engagement
Plainsboro, NJ, US
Internship
Onsite
InternNovo Nordisk is a global pharmaceutical company dedicated to improving the lives of patients with chronic diseases. The internship role focuses on supporting the Community Engagement team by driving sustainable demand for rare bleeding disorders and sickle cell disease, while helping to measure impact within the community.
BiotechnologyHealth CareMedicalPharmaceutical
No H1B
Responsibilities
Support the Community Engagement team in driving sustainable demand for rare bleeding disorders & sickle cell disease
Help identify ways the Community Engagement Team can define, articulate and measure impact with patients, caregivers and their communities
Qualification
Required
Must be a current student enrolled or recently graduated (graduation date no earlier than May 2026) at/from an accredited college or university pursuing at least a bachelor's degree
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc
Preferred
A completed or in progress undergraduate degree in Business Administration, Marketing, Finance or a related discipline preferred
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Founded in 1923
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Leadership Team
Lars Fruergaard Jørgensen
President and CEO
Lars Sorensen
President & CEO
Recent News
Labiotech UG
2026-01-24
bloomberglaw.com
2026-01-24
Company data provided by crunchbase